+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PMO Drug Market by Drug Type (Biologic, Pmo Oligomer, Small Molecule), Route Administration (Injection, Oral, Topical), Distribution Channel, Indication, Dosage Form, End User - Global Forecast 2025-2030- Product Image
PMO Drug Market by Drug Type (Biologic, Pmo Oligomer, Small Molecule), Route Administration (Injection, Oral, Topical), Distribution Channel, Indication, Dosage Form, End User - Global Forecast 2025-2030- Product Image
Sale

PMO Drug Market by Drug Type (Biologic, Pmo Oligomer, Small Molecule), Route Administration (Injection, Oral, Topical), Distribution Channel, Indication, Dosage Form, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6131251
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The PMO drug sector has emerged as a critical frontier in pharmaceutical innovation, bridging the gap between small molecule therapeutics and complex biologics. Advances in oligonucleotide chemistry and delivery technologies have propelled phosphorodiamidate morpholino oligomers into the spotlight, promising targeted treatments for rare neuromuscular disorders, viral infections, and beyond. This executive summary provides a succinct yet substantive orientation to the factors shaping this dynamic arena, equipping decision-makers with the context needed to understand the multifaceted pressures and opportunities that define the market environment.

Drawing upon rigorous primary and secondary research, this section lays out the core themes that the report will explore in further depth. Readers will find a structured pathway through the transformative shifts in innovation strategies, the implications of recent tariff policies, segmentation-driven insights, regional nuances, leading company profiles, strategic recommendations, and the methodological rigor underpinning the study. By setting this foundational context, stakeholders can align their resource allocation, R&D priorities, and partnership strategies with the emerging contours of PMO drug development and commercialization.

Unveiling Pivotal Transformative Shifts Redefining Competitive Dynamics and Innovation Trajectories within the PMO Drug Landscape in 2025 and Beyond

The PMO drug landscape is undergoing a paradigm shift driven by breakthroughs in molecular design, advanced delivery platforms, and data-enabled clinical decision-making. Innovations in chemistries that enhance target specificity and cellular uptake have accelerated the translational pipeline, while modular delivery vehicles-from lipid nanoparticles to conjugated peptides-have expanded the therapeutic reach of morpholino oligomers. These technological strides are complemented by an evolving regulatory climate that increasingly favors accelerated approval pathways for therapies addressing unmet medical needs, particularly in rare and orphan disease categories.

Simultaneously, the integration of real-world evidence and digital health solutions into clinical development frameworks is reshaping trial design and patient engagement, enabling adaptive dosing strategies and remote monitoring. Partnerships between biotech pioneers and established pharmaceutical firms continue to proliferate, reflecting a broader trend toward collaborative ecosystems that leverage complementary capabilities. As payers and providers engage with novel reimbursement models, the interplay of value-based contracting and outcome-driven pricing will further define the competitive contours of the market. Taken together, these transformative shifts are setting the stage for a new era of PMO drug innovation, where agility, strategic alliances, and patient-centric approaches will determine success.

Assessing the Cumulative Consequences of US Tariff Implementations on PMO Drug Supply Chains Regulatory Costs and Market Accessibility in 2025

The introduction of new tariff measures on critical raw materials and intermediates in 2025 has introduced a layer of complexity to global PMO drug supply chains. Costs associated with importing specialized reagents, oligonucleotide backbones, and delivery component precursors have risen, prompting companies to revisit sourcing strategies and inventory management protocols. Regulatory compliance burdens have also increased, as customs classifications and valuation methodologies for advanced therapeutic materials evolve in response to trade policy adjustments.

In response, key players have adopted nearshoring strategies and diversified supplier networks to mitigate import duty impacts while maintaining production continuity. Contract development and manufacturing organizations have renegotiated long-term agreements to reflect adjusted cost structures, and some innovators are restructuring their manufacturing footprints to bring critical stages of synthesis in-house. While these adjustments have entailed upfront investments, they also promise greater resilience against future policy shifts. Moreover, accelerated dialogue between industry and trade authorities has begun to smooth procedural frictions, illustrating how proactive engagement can alleviate some of the most pronounced tariff-related headwinds.

Distilling Actionable Insights from Multidimensional PMO Drug Market Segmentations Highlighting Therapeutic Types Administration Routes and End User Dynamics

A multidimensional examination of PMO drug market segmentations reveals the diverse avenues through which stakeholders can tailor their strategies. By drug type, the market spans large-molecule biologics, morpholino oligomers, and traditional small molecule therapies-each category presenting distinct scientific challenges and commercial pathways. When considering routes of administration, the landscape extends from injectable formats, including intramuscular, intravenous, and subcutaneous deliveries, to oral modalities defined by capsules, liquids, and tablets, as well as topical applications. Distribution channels range from hospital pharmacies, which offer direct engagement with clinical centers, to online pharmacies that cater to digitally enabled patients and traditional retail outlets that drive broad accessibility.

Further segmentation by indication underscores the therapeutic focus of PMO drugs. Within infectious diseases, bacterial and viral infection targets demand divergent dosing regimens and resistance management strategies, while neuromuscular disorder applications, such as Duchenne muscular dystrophy and spinal muscular atrophy, necessitate specialized safety monitoring frameworks. Dosage form segmentation includes capsules, injectables, liquids, and tablets, each requiring unique stability and bioavailability considerations. Lastly, end-user classification highlights home care settings, hospitals, and specialty clinics, illuminating pathways for patient support programs and clinical education initiatives. This holistic view of market segmentations enables more precise targeting of R&D investments, manufacturing scale-up plans, and go-to-market tactics.

Key Regional Insights across Americas EMEA and Asia-Pacific to Uncover Growth Drivers Distribution Complexities and Policy Landscapes Shaping PMO Drug Markets

Regional landscapes are shaping distinct growth narratives for PMO drugs, with the Americas capitalizing on robust clinical trial networks, established reimbursement frameworks, and strong biomanufacturing infrastructure. In North America, close collaboration between academic centers and biotech firms accelerates early-stage research, while Latin American markets show increasing interest in expanding patient access programs and public-private partnerships to address unmet needs.

In EMEA, regulatory harmonization efforts and pan-European health technology assessments are influencing market entry strategies, with stakeholders strategically aligning dossier submissions to meet varying national requirements. The United Kingdom’s post-Brexit framework presents both challenges and opportunities for innovators seeking centralized approval routes. Meanwhile, Asia-Pacific markets are characterized by rapid growth potential driven by rising healthcare expenditure, expanding specialty care facilities, and government initiatives to bolster domestic biopharmaceutical capabilities. Countries such as China, Japan, and Australia are investing heavily in local GMP facilities and clinical research capabilities, reflecting a shift toward self-sufficiency and innovative therapeutics adoption across the region.

Profiling Influential Companies Driving Innovation Strategic Partnerships and Competitive Differentiation within the Global PMO Drug Market Ecosystem

Leading companies in the PMO drug space are differentiating themselves through proprietary chemistry platforms, clinical pipeline breadth, and strategic alliances. Some pioneers focus on next-generation morpholino backbones engineered for enhanced tissue penetration and reduced off-target effects, while others invest in conjugation technologies that improve pharmacokinetics and patient tolerability. Collaborative partnerships, including in-licensing agreements and co-development deals with academic innovators, have become a core strategy to accelerate time-to-clinic and share developmental risk.

Moreover, contract development and manufacturing organizations are expanding their service offerings to include end-to-end capabilities, from custom oligonucleotide synthesis to formulation and analytical support. This evolution reflects growing demand for integrated solutions that bridge early-stage research with commercial-scale production. Companies that effectively harness digital tools-ranging from AI-driven sequence design to remote monitoring of manufacturing processes-stand to gain a competitive edge by reducing cycle times and ensuring consistent quality. As patent landscapes evolve and biosimilar entrants emerge, market leaders will need to continuously innovate around value-added services, patient engagement platforms, and lifecycle management strategies.

Formulating Actionable Strategic Recommendations for Industry Leaders to Navigate Regulatory Complexities Technological Disruptions and Market Dynamics in PMO Drugs

Industry leaders should proactively diversify their supply chains to incorporate regional manufacturing hubs and multiple raw material suppliers, thereby reducing dependence on any single source and cushioning against policy-induced disruptions. Investing in modular, flexible production facilities capable of rapid scale-up can also enhance responsiveness to emerging clinical and commercial demands. In parallel, forming cross-sector alliances that pool expertise in delivery technologies, digital health platforms, and regulatory strategy will accelerate time-to-market and distribute development risk.

To maximize patient impact and market adoption, organizations must engage payers early through value demonstration studies that integrate real-world evidence, health economics models, and patient-reported outcomes. Developing comprehensive patient support programs, including digital adherence tools and remote care coordination, can further differentiate offerings in competitive therapeutic areas. Finally, embracing data analytics and machine learning for predictive process control and sequence optimization will improve development efficiency and ensure consistent product quality. By executing on these strategic priorities, leaders can navigate regulatory complexities, technological disruptions, and shifting market dynamics with greater confidence and agility.

Outlining a Robust Multistage Research Methodology Incorporating Qualitative and Quantitative Analyses Expert Consultations and Data Validation Protocols

This research employed a multistage approach combining qualitative and quantitative methodologies to ensure robust, actionable insights. Initially, secondary research consolidated existing scientific literature, patent databases, regulatory filings, and public company disclosures to frame the market’s technical and commercial contours. Primary research followed, encompassing in-depth interviews with key opinion leaders, industry executives, regulatory experts, and clinical practitioners to validate assumptions and uncover emerging trends.

Quantitative data analysis included triangulation of public financial records, proprietary databases, and clinical trial registries to map competitive positioning and investment flows. The study’s data validation protocols featured cross-referencing of sources and iterative feedback loops with subject matter experts, ensuring high fidelity of findings. Limitations of the methodology-such as potential delays in publication cycles and evolving regulatory landscapes-were addressed through regular updates and scenario planning exercises. This comprehensive framework delivers a nuanced understanding of PMO drug market dynamics and supports informed decision-making.

Concluding Reflections on Strategic Imperatives Future Outlook and the Transformational Opportunities Shaping the Next Era of PMO Drug Innovation and Adoption

The rapid evolution of PMO therapies underscores the need for strategic agility, collaborative innovation, and data-driven decision-making. As scientific advances continue to unlock new therapeutic possibilities, stakeholders must remain vigilant to policy shifts, supply chain vulnerabilities, and emerging competitive pressures. The insights presented throughout this summary demonstrate the importance of a segmentation-focused approach, regional adaptability, and proactive engagement with regulatory and reimbursement bodies.

Looking ahead, the convergence of advanced oligonucleotide design, precision delivery platforms, and integrated digital health tools will shape the next wave of breakthroughs. Organizations that align their R&D pipelines with patient-centric value frameworks and operational excellence will be best positioned to capture long-term growth. By embracing the recommendations and leveraging the detailed analyses within this report, decision-makers can navigate the complexities of the PMO drug market and capitalize on transformative opportunities poised to redefine pharmaceutical innovation.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Drug Type
    • Biologic
    • Pmo Oligomer
    • Small Molecule
  • Route Administration
    • Injection
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Oral
      • Capsule
      • Liquid
      • Tablet
    • Topical
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Indication
    • Infectious Diseases
      • Bacterial Infections
      • Viral Infections
    • Neuromuscular Disorders
      • Duchenne Muscular Dystrophy
      • Spinal Muscular Atrophy
  • Dosage Form
    • Capsule
    • Injectable
    • Liquid
    • Tablet
  • End User
    • Home Care Settings
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of romosozumab therapies driven by recent positive cardiovascular safety data
5.2. Intensified competition from biosimilar teriparatide launches eroding market share of originator brands
5.3. Development of oral small molecule Wnt pathway modulators as alternatives to injectable osteoporosis drugs
5.4. Increasing use of digital adherence tools and remote patient monitoring in PMO treatment regimens
5.5. Expansion of PMO drug reimbursement policies across emerging APAC markets boosting regional growth
5.6. Growing emphasis on real-world evidence from postmarketing registries to support payer negotiations
5.7. Strategic partnerships between pharma and tech firms for AI-driven osteoporosis risk prediction
5.8. Launch of long-acting injectable denosumab biosimilars reshaping treatment duration and cost dynamics
5.9. Implementation of outcomes-based contracting models for high-cost osteoporosis biologics in US hospitals
5.10. Shift towards patient-centric care pathways integrating fracture liaison services with osteoporosis management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PMO Drug Market, by Drug Type
8.1. Introduction
8.2. Biologic
8.3. Pmo Oligomer
8.4. Small Molecule
9. PMO Drug Market, by Route Administration
9.1. Introduction
9.2. Injection
9.2.1. Intramuscular
9.2.2. Intravenous
9.2.3. Subcutaneous
9.3. Oral
9.3.1. Capsule
9.3.2. Liquid
9.3.3. Tablet
9.4. Topical
10. PMO Drug Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. PMO Drug Market, by Indication
11.1. Introduction
11.2. Infectious Diseases
11.2.1. Bacterial Infections
11.2.2. Viral Infections
11.3. Neuromuscular Disorders
11.3.1. Duchenne Muscular Dystrophy
11.3.2. Spinal Muscular Atrophy
12. PMO Drug Market, by Dosage Form
12.1. Introduction
12.2. Capsule
12.3. Injectable
12.4. Liquid
12.5. Tablet
13. PMO Drug Market, by End User
13.1. Introduction
13.2. Home Care Settings
13.3. Hospitals
13.4. Specialty Clinics
14. Americas PMO Drug Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa PMO Drug Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific PMO Drug Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Amgen Inc.
17.3.2. Eli Lilly and Company
17.3.3. F. Hoffmann-La Roche Ltd
17.3.4. Novartis AG
17.3.5. GlaxoSmithKline plc
17.3.6. Merck & Co., Inc.
17.3.7. Johnson & Johnson
17.3.8. Pfizer Inc.
17.3.9. Sanofi S.A.
17.3.10. Teva Pharmaceutical Industries Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PMO DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PMO DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PMO DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PMO DRUG MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PMO DRUG MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PMO DRUG MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PMO DRUG MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PMO DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PMO DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PMO DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PMO DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PMO DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PMO DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PMO DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. PMO DRUG MARKET: RESEARCHAI
FIGURE 28. PMO DRUG MARKET: RESEARCHSTATISTICS
FIGURE 29. PMO DRUG MARKET: RESEARCHCONTACTS
FIGURE 30. PMO DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PMO DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PMO DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PMO DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PMO DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PMO DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PMO DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PMO DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PMO DRUG MARKET SIZE, BY BIOLOGIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PMO DRUG MARKET SIZE, BY BIOLOGIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PMO DRUG MARKET SIZE, BY PMO OLIGOMER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PMO DRUG MARKET SIZE, BY PMO OLIGOMER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PMO DRUG MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PMO DRUG MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PMO DRUG MARKET SIZE, BY INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PMO DRUG MARKET SIZE, BY INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PMO DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PMO DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PMO DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PMO DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PMO DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PMO DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PMO DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PMO DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PMO DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PMO DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PMO DRUG MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PMO DRUG MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PMO DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PMO DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PMO DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PMO DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PMO DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PMO DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PMO DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PMO DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PMO DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PMO DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PMO DRUG MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PMO DRUG MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PMO DRUG MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PMO DRUG MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PMO DRUG MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PMO DRUG MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PMO DRUG MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PMO DRUG MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PMO DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PMO DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PMO DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PMO DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PMO DRUG MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PMO DRUG MARKET SIZE, BY LIQUID, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PMO DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PMO DRUG MARKET SIZE, BY TABLET, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PMO DRUG MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PMO DRUG MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PMO DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PMO DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PMO DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PMO DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS PMO DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS PMO DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES PMO DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES PMO DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 129. CANADA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 130. CANADA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 131. CANADA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 134. CANADA PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 135. CANADA PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 136. CANADA PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 137. CANADA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. CANADA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. CANADA PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 140. CANADA PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 141. CANADA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 142. CANADA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 143. CANADA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 144. CANADA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 145. CANADA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 146. CANADA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 147. CANADA PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. CANADA PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. MEXICO PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 150. MEXICO PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 151. MEXICO PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 154. MEXICO PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 155. MEXICO PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 156. MEXICO PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 157. MEXICO PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. MEXICO PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. MEXICO PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 160. MEXICO PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 162. MEXICO PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 163. MEXICO PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 164. MEXICO PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 165. MEXICO PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 166. MEXICO PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 167. MEXICO PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. MEXICO PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA PMO DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. GERMANY PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 252. GERMANY PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 253. GERMANY PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. GERMANY PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. GERMANY PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 256. GERMANY PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 257. GERMANY PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 258. GERMANY PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 259. GERMANY PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. GERMANY PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. GERMANY PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. GERMANY PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. GERMANY PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 264. GERMANY PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 265. GERMANY PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 266. GERMANY PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 267. GERMANY PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 268. GERMANY PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 269. GERMANY PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. GERMANY PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. FRANCE PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 272. FRANCE PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 273. FRANCE PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. FRANCE PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. FRANCE PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 276. FRANCE PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 277. FRANCE PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 278. FRANCE PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 279. FRANCE PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. FRANCE PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. FRANCE PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. FRANCE PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. FRANCE PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 284. FRANCE PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 285. FRANCE PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 286. FRANCE PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 288. FRANCE PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 289. FRANCE PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. FRANCE PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 309. RUSSIA PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. RUSSIA PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. ITALY PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 312. ITALY PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 313. ITALY PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 314. ITALY PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 315. ITALY PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 316. ITALY PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 317. ITALY PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 318. ITALY PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 319. ITALY PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. ITALY PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. ITALY PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. ITALY PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. ITALY PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 324. ITALY PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 325. ITALY PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 326. ITALY PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 327. ITALY PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 328. ITALY PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 329. ITALY PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 330. ITALY PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 331. SPAIN PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 332. SPAIN PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 333. SPAIN PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 334. SPAIN PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 335. SPAIN PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 336. SPAIN PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 337. SPAIN PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 338. SPAIN PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 339. SPAIN PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 340. SPAIN PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 341. SPAIN PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 342. SPAIN PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 343. SPAIN PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 344. SPAIN PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 345. SPAIN PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 346. SPAIN PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 347. SPAIN PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 348. SPAIN PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 349. SPAIN PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 350. SPAIN PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 351. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 352. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 353. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 354. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 355. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 356. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 357. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 358. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 359. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 360. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 361. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 362. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 363. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 364. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 365. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2018-2024 (USD MILLION)
TABLE 366. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY NEUROMUSCULAR DISORDERS, 2025-2030 (USD MILLION)
TABLE 367. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 368. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 369. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 370. UNITED ARAB EMIRATES PMO DRUG MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 371. SAUDI ARABIA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 372. SAUDI ARABIA PMO DRUG MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 373. SAUDI ARABIA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 374. SAUDI ARABIA PMO DRUG MARKET SIZE, BY ROUTE ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 375. SAUDI ARABIA PMO DRUG MARKET SIZE, BY INJECTION, 2018-2024 (USD MILLION)
TABLE 376. SAUDI ARABIA PMO DRUG MARKET SIZE, BY INJECTION, 2025-2030 (USD MILLION)
TABLE 377. SAUDI ARABIA PMO DRUG MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 378. SAUDI ARABIA PMO DRUG MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 379. SAUDI ARABIA PMO DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 380. SAUDI ARABIA PMO DRUG MARKET SIZE, BY DISTRIBUT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PMO Drug market report include:
  • Amgen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Related Reports

Antibody-PMO Conjugates Market by Therapeutic Area (Genetic Disorders, Oncology, Rare Diseases), End User (Academic Institutions, Biotech Companies, Contract Research Organizations), Product Stage, Conjugation Type, Technology - Global Forecast 2025-2030 - Product Image

Antibody-PMO Conjugates Market by Therapeutic Area (Genetic Disorders, Oncology, Rare Diseases), End User (Academic Institutions, Biotech Companies, Contract Research Organizations), Product Stage, Conjugation Type, Technology - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
PMO Conjugates Market by Product Type (Antibody PMO Conjugates, Peptide PMO Conjugates), Application (Neuromuscular Diseases, Oncology, Rare Genetic Disorders), End User, Delivery Mode, Molecule Type - Global Forecast 2025-2030 - Product Image

PMO Conjugates Market by Product Type (Antibody PMO Conjugates, Peptide PMO Conjugates), Application (Neuromuscular Diseases, Oncology, Rare Genetic Disorders), End User, Delivery Mode, Molecule Type - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Project Management Best Practices: Achieving Global Excellence. Edition No. 4 - Product Image

Project Management Best Practices: Achieving Global Excellence. Edition No. 4

  • Book
  • 784 Pages
  • Global
Project Management Best Practices. Achieving Global Excellence. 3rd Edition - Product Image

Project Management Best Practices. Achieving Global Excellence. 3rd Edition

  • Book
  • 792 Pages
  • Global
2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA - Product Image

2024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA

  • Report
  • 84 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.